Kevin Xie is the founder of Gracell Biotechnologies. Gracell Biotechnologies has raised $100M in total funding. Latest round: Series C.
Kevin Xie is the CFO of Gracell Biotechnology. The company, founded in 2017 in China, is a global clinical-stage biopharmaceutical company focused on developing cell therapies for cancer treatment. With two pioneering platforms, FasTCAR and TruUCAR, Gracell aims to provide highly efficacious and affordable CAR-T cell therapies.
Full founder directory · Investor directory · Company funding database · Fundraising library